This Could Be the Next Big Pharma Buyout
Three Motley Fool analysts tell investors which three companies they think would be ripe for an acquisition.
Is It Time to Buy This Growth Stock?
Specialty and generic drugmaker Actavis has been going through a rapid growth spurt, spurred by its numerous acquisitions. After completing a mega merger with Botox-maker Allergan, can the uptrend continue?
The 3 Most Memorable Moments in Healthcare This Year
Three Motley Fool analysts tell investors what they believe are the year's most memorable events in the healthcare sector.